WO1999026927A3 - Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central - Google Patents
Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central Download PDFInfo
- Publication number
- WO1999026927A3 WO1999026927A3 PCT/US1998/024833 US9824833W WO9926927A3 WO 1999026927 A3 WO1999026927 A3 WO 1999026927A3 US 9824833 W US9824833 W US 9824833W WO 9926927 A3 WO9926927 A3 WO 9926927A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metabotropic glutamate
- nervous system
- central nervous
- receptor antagonists
- glutamate receptor
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title abstract 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13625098A IL136250A0 (en) | 1997-11-21 | 1998-11-20 | Metabotropic glutamate receptor antagonist compounds |
MXPA00004940A MXPA00004940A (es) | 1997-11-21 | 1998-11-20 | Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central. |
JP2000522085A JP2001524468A (ja) | 1997-11-21 | 1998-11-20 | 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト |
AU15317/99A AU771358B2 (en) | 1997-11-21 | 1998-11-20 | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
CA002311131A CA2311131A1 (fr) | 1997-11-21 | 1998-11-20 | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central |
NZ505207A NZ505207A (en) | 1997-11-21 | 1998-11-20 | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
EP98959535A EP1037878A2 (fr) | 1997-11-21 | 1998-11-20 | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central |
US09/573,347 US6429207B1 (en) | 1997-11-21 | 2000-05-19 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
IL136250A IL136250A (en) | 1997-11-21 | 2000-05-21 | Metabotropic glutamate receptor antagonist compounds |
US10/211,523 US7053104B2 (en) | 1997-11-21 | 2002-08-05 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
AU2004202776A AU2004202776B2 (en) | 1997-11-21 | 2004-06-17 | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6675897P | 1997-11-21 | 1997-11-21 | |
US60/066,758 | 1997-11-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/573,347 Continuation-In-Part US6429207B1 (en) | 1997-11-21 | 2000-05-19 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999026927A2 WO1999026927A2 (fr) | 1999-06-03 |
WO1999026927A3 true WO1999026927A3 (fr) | 1999-10-21 |
Family
ID=22071510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/024833 WO1999026927A2 (fr) | 1997-11-21 | 1998-11-20 | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1037878A2 (fr) |
JP (1) | JP2001524468A (fr) |
CN (2) | CN1554649A (fr) |
AU (2) | AU771358B2 (fr) |
CA (1) | CA2311131A1 (fr) |
IL (2) | IL136250A0 (fr) |
MX (1) | MXPA00004940A (fr) |
NZ (1) | NZ505207A (fr) |
WO (1) | WO1999026927A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895050B2 (en) | 2003-08-06 | 2014-11-25 | Senomyx, Inc. | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1059090A4 (fr) * | 1998-03-03 | 2002-02-27 | Yamanouchi Pharma Co Ltd | Medicaments contre l'infarcissement du cerveau |
GB9823847D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
GB9823845D0 (en) | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
CN1361768A (zh) * | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
AU6420700A (en) * | 1999-08-05 | 2001-03-05 | Prescient Neuropharma Inc. | Novel 1,4-benzodiazepine compounds and derivatives thereof |
EP1582519A3 (fr) * | 1999-08-19 | 2005-12-21 | Nps Pharmaceuticals, Inc. | Composes heteropolycycliques et leur utilisation comme antagonistes des recepteurs glutamiques metabotropes |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
DE60023318T2 (de) * | 1999-08-19 | 2006-07-20 | NPS Pharmaceuticals, Inc., Salt Lake City | Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren |
JP3886805B2 (ja) * | 1999-10-15 | 2007-02-28 | エフ.ホフマン−ラ ロシュ アーゲー | ベンゾジアゼピン誘導体 |
BR0014859A (pt) * | 1999-10-15 | 2002-07-16 | Hoffmann La Roche | Derivados de benzodiazepina |
GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
JP2004510764A (ja) * | 2000-10-02 | 2004-04-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 代謝共役型グルタミン酸受容体拮抗剤 |
TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
MXPA04002785A (es) * | 2001-09-24 | 2004-07-29 | Elan Pharm Inc | Aminas sustituidas para tratamiento de enfermedad de alzheimer. |
NZ535438A (en) | 2002-03-29 | 2006-08-31 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
CN100357283C (zh) * | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
CN101723941A (zh) | 2002-08-09 | 2010-06-09 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑 |
WO2004056744A1 (fr) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
BRPI0406810A (pt) * | 2003-01-31 | 2005-12-27 | Astrazeneca Ab | Compostos, processos de preparação e uso respectivos, composição farmacêutica e métodos de inibição da ativação dos receptores de mglur do grupo i e de tratamento de desordens mediadas pelos mesmos |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
US7501416B2 (en) | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
KR101192861B1 (ko) | 2004-05-07 | 2012-10-19 | 얀센 파마슈티카 엔.브이. | 11-베타 하이드록시스테로이드 탈수소효소 저해제로서의피롤리딘-2-온 및 피페리딘-2-온 유도체 |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
MY141198A (en) | 2004-08-30 | 2010-03-31 | Janssen Pharmaceutica Nv | Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
BRPI0515121A (pt) * | 2004-08-30 | 2008-07-08 | Janssen Pharmaceutica Nv | derivados da n-2 adamantil-2-fenóxi acetamida como inibidores da 11-beta hidroxiesteróide desidrogenase |
DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
JP4734346B2 (ja) | 2005-02-04 | 2011-07-27 | セノミックス インコーポレイテッド | 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用 |
EA200701745A1 (ru) | 2005-03-17 | 2008-06-30 | Пфайзер, Инк. | Циклопропанкарбоксамидные производные |
GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
AR055329A1 (es) | 2005-06-15 | 2007-08-15 | Senomyx Inc | Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor |
MX2007015863A (es) | 2005-06-17 | 2008-04-02 | Apogee Biotechnology Corp | Inhibidores de esfingosina cinasa. |
US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
CN101277934A (zh) * | 2005-08-12 | 2008-10-01 | 阿斯利康(瑞典)有限公司 | 使代谢型谷氨酸-受体-增效的异吲哚酮 |
WO2007037543A1 (fr) * | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | Dérivé de biarylamide |
WO2007045876A1 (fr) * | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co. Kgaa | Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate |
KR20080076962A (ko) * | 2005-12-20 | 2008-08-20 | 노파르티스 아게 | 대사성 글루타메이트 수용체 조절제로서의 니코틴산 유도체 |
TW200804281A (en) | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
TWI674069B (zh) | 2006-04-21 | 2019-10-11 | 美商賽諾米克斯公司 | 包含高度鮮味風味劑之可食用組合物及其製造方法 |
TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
PT2054416E (pt) | 2006-08-04 | 2011-04-06 | Merz Pharma Gmbh & Co Kgaa | Pirazolopirimidinas substituídas, um processo para a sua preparação e a sua utilização como medicamento |
EP2091944B1 (fr) | 2006-11-17 | 2011-05-18 | Pfizer Inc. | Composés bicyclocarboxyamides substitués |
SI2083811T1 (sl) | 2006-11-22 | 2017-02-28 | Clinical Research Associates, Llc | Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma |
AR065806A1 (es) | 2007-03-22 | 2009-07-01 | Astrazeneca Ab | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. |
AU2008240802B2 (en) | 2007-04-19 | 2012-07-05 | F. Hoffmann-La Roche Ag | Dihydro-benzo[B][1,4]diazepin-2-one sulfonamide derivatives |
TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途 |
CN101348461B (zh) * | 2007-07-17 | 2011-10-05 | 西安利君制药有限责任公司 | 用于老年痴呆症治疗的n-(3-吡啶甲酰氧基)-3,5-二甲基-1-金刚烷胺或其可药用盐 |
EP2064959B1 (fr) | 2007-10-31 | 2012-07-25 | Symrise AG | Néomenthylamides aromatiques en tant qu'agents aromatisants |
US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
US8211882B2 (en) * | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
US7790760B2 (en) | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
ES2432070T3 (es) | 2009-02-24 | 2013-11-29 | Respiratorius Ab | Diazaheteroarilos broncodilatadores novedosos |
US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (fr) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés |
WO2012006760A1 (fr) * | 2010-07-14 | 2012-01-19 | Merck Sharp & Dohme Corp. | Composés tricycliques comme modulateurs allostériques des récepteurs métabotropes au glutamate |
WO2012009646A1 (fr) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et de troubles associés |
CN103391926A (zh) * | 2010-11-30 | 2013-11-13 | 拜耳知识产权有限责任公司 | 嘧啶衍生物及其作为病虫害防治剂的应用 |
KR102529578B1 (ko) * | 2014-08-29 | 2023-05-09 | (주)아모레퍼시픽 | 신규 아다만탄 유도체 화합물 |
CN114539170B (zh) * | 2021-12-31 | 2023-05-16 | 华南农业大学 | 一种用于同时检测金刚烷胺、喹乙醇、氯霉素的半抗原、人工抗原及其制备方法和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2050074A1 (de) * | 1969-10-27 | 1971-05-06 | E R Squibb & Sons Ine , New York, NY (V St A.) | 4 (Adamantylaminoalkylamino) chinoline, deren Salze und Derivate, sowie Verfahren zu ihrer Herstellung und ihre Verwendung |
US3632581A (en) * | 1968-10-08 | 1972-01-04 | American Home Prod | Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products |
DE2728248A1 (de) * | 1976-06-24 | 1978-01-05 | Debat Lab | Nitroxolinderivate |
EP0002066A1 (fr) * | 1977-11-22 | 1979-05-30 | Teva Pharmaceutical Industries Limited | Adamantyl-2 hydrazines et compositions pharmaceutiques les contenant |
EP0407192A2 (fr) * | 1989-07-07 | 1991-01-09 | Meiji Seika Kabushiki Kaisha | Dérivés acyloxy-4-quinoléine et compositions insecticides et acaricides les contenant |
JPH07179371A (ja) * | 1993-12-21 | 1995-07-18 | Canon Inc | 液晶性化合物、それを含む液晶組成物、それを用いた液晶素子、それらを用いた表示方法、及び表示装置 |
WO1996005818A1 (fr) * | 1994-08-19 | 1996-02-29 | Nps Pharmaceuticals, Inc. | Procedes et composes actifs au niveau des recepteurs de glutamate metabotropiques, destines au traitement d'affections et de troubles neurologiques |
WO1996040641A1 (fr) * | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | Derives de sulfonamides servant a moduler l'adherence cellulaire |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2509728A1 (fr) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
IE902295A1 (en) * | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
DE69128682T2 (de) * | 1990-03-28 | 1998-06-04 | Otsuka Pharma Co Ltd | Chinolinderivat, antiulcus-mittel das dieses derivat enthält und darstellung dieses derivates |
JPH0441425A (ja) * | 1990-06-07 | 1992-02-12 | Tanabe Seiyaku Co Ltd | 5―リポキシゲナーゼ阻害剤 |
US5663179A (en) * | 1992-07-10 | 1997-09-02 | Laboratoires Glaxo Sa | Certain isoquinoline derivatives having anti-tumor properties |
ATE199721T1 (de) * | 1994-07-04 | 2001-03-15 | Takeda Chemical Industries Ltd | Phosphonsäure verbindungen imre herstellung und verwendung |
JP2002501506A (ja) * | 1997-05-03 | 2002-01-15 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ドーパミンd▲下3▼受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体 |
-
1998
- 1998-11-20 IL IL13625098A patent/IL136250A0/xx not_active IP Right Cessation
- 1998-11-20 MX MXPA00004940A patent/MXPA00004940A/es active IP Right Grant
- 1998-11-20 JP JP2000522085A patent/JP2001524468A/ja active Pending
- 1998-11-20 CN CNA2004100474998A patent/CN1554649A/zh active Pending
- 1998-11-20 CN CNB98813148XA patent/CN1158264C/zh not_active Expired - Fee Related
- 1998-11-20 WO PCT/US1998/024833 patent/WO1999026927A2/fr active Application Filing
- 1998-11-20 NZ NZ505207A patent/NZ505207A/en unknown
- 1998-11-20 EP EP98959535A patent/EP1037878A2/fr not_active Withdrawn
- 1998-11-20 AU AU15317/99A patent/AU771358B2/en not_active Ceased
- 1998-11-20 CA CA002311131A patent/CA2311131A1/fr not_active Abandoned
-
2000
- 2000-05-21 IL IL136250A patent/IL136250A/en unknown
-
2004
- 2004-06-17 AU AU2004202776A patent/AU2004202776B2/en not_active Ceased
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632581A (en) * | 1968-10-08 | 1972-01-04 | American Home Prod | Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products |
DE2050074A1 (de) * | 1969-10-27 | 1971-05-06 | E R Squibb & Sons Ine , New York, NY (V St A.) | 4 (Adamantylaminoalkylamino) chinoline, deren Salze und Derivate, sowie Verfahren zu ihrer Herstellung und ihre Verwendung |
DE2728248A1 (de) * | 1976-06-24 | 1978-01-05 | Debat Lab | Nitroxolinderivate |
EP0002066A1 (fr) * | 1977-11-22 | 1979-05-30 | Teva Pharmaceutical Industries Limited | Adamantyl-2 hydrazines et compositions pharmaceutiques les contenant |
EP0407192A2 (fr) * | 1989-07-07 | 1991-01-09 | Meiji Seika Kabushiki Kaisha | Dérivés acyloxy-4-quinoléine et compositions insecticides et acaricides les contenant |
JPH07179371A (ja) * | 1993-12-21 | 1995-07-18 | Canon Inc | 液晶性化合物、それを含む液晶組成物、それを用いた液晶素子、それらを用いた表示方法、及び表示装置 |
WO1996005818A1 (fr) * | 1994-08-19 | 1996-02-29 | Nps Pharmaceuticals, Inc. | Procedes et composes actifs au niveau des recepteurs de glutamate metabotropiques, destines au traitement d'affections et de troubles neurologiques |
WO1996040641A1 (fr) * | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | Derives de sulfonamides servant a moduler l'adherence cellulaire |
Non-Patent Citations (16)
Title |
---|
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 12. Bd.", 1929, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101991 * |
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 9. Bd.", 1926, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101990 * |
CHEMICAL ABSTRACTS, vol. 115, no. 7, 19 August 1991, Columbus, Ohio, US; abstract no. 70978a, N. S. KOZLOV ET AL.: "Synthesis of adamantane-type beta-amino ketones" page 733; XP002101994 * |
F. HONG ET AL.: "Design, synthesis and pharmacological test of a quinoline based, nonpeptidic analogue of neurotensin(8-13)", J. CHEM. SOC., PERKIN TRANS. 1, vol. 14, 1997, pages 2083 - 2088, XP002101983 * |
F. SZTARICSKAI ET AL.: "Synthese und virushemmende in-vitro-Wirkung neuerer 1-substituierter Adamantanderivate", PHARMAZIE, vol. 30, no. 9, 1975, pages 571 - 581, XP002101986 * |
G. FENECH ET AL.: "Derivati amidici dell'acido 1-adamantancarbossilico a potenziale attivita antivirale ed antitumorale", BOLL. CHIM. FARM., vol. 118, no. 2, 1979, pages 78 - 87, XP002101981 * |
H. ZIMMER, H. D. BENSON: "Kondensierte Imidazole; Versuche zur Synthese des 13,16- und 14,16-Diazasterin-Gerüstes", CHIMIA, vol. 26, no. 3, 1972, pages 131 - 133, XP002101985 * |
H.-G. BOIT: "Beilsteins Handbuch der Organischen Chemie", 1970, SPRINGER-VERLAG, BERLIN, XP002101992 * |
K. H. KIM ET AL.: "Quantitative Structure-Activity Relationship in 1-Aryl-2-(alkylamino)ethanol Antimalarials", J. MED. CHEM., vol. 22, no. 4, 1979, pages 366 - 391, XP002101988 * |
L. C. MARCH ET AL.: "Antimalarials. 2. Dihydro-1,3-oxazinoquinolines and Dihydro-1,3-pyridobenzoxazines", J. MED. CHEM., vol. 16, no. 4, 1973, pages 337 - 342, XP002101989 * |
M. ZANISI ET AL.: "Excitatory amino acids as modulators of gonadotropin secretion", AMINO ACIDS, vol. 6, no. 1, 1994, pages 47 - 56, XP002101984 * |
N. G. KOZLOV, G. P. KOROTISHOVA: "Synthesis of 1-(1-adamantyl)-2,3-dihydroxy-3-R-1-propanones", ZH. OBSHCH. KHIM., vol. 66, no. 12, 1996, pages 2039 - 2041, XP002101987 * |
PATENT ABSTRACTS OF JAPAN vol. 095, no. 010 30 November 1995 (1995-11-30) * |
R. LUCKENBACH: "Beilsteins Handbuch der Organischen Chemie, 3. u. 4. Eg., 22. Bd.", 1979, SPRINGER-VERLAG, BERLIN, XP002101993 * |
S. S. SABRI ET AL.: "Syntheses and Antibacterial Activity of Some New N-(3-Methyl-2-quinoxalyl) Amino Alcohols and Amine 1,4-Dioxides", J. CHEM. ENG. DATA, vol. 29, no. 2, 1984, pages 229 - 231, XP002101982 * |
VESTSI AKAD. NAVUK BSSR, SER. KHIM. NAVUK, no. 1, 1991, pages 60 - 65 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895050B2 (en) | 2003-08-06 | 2014-11-25 | Senomyx, Inc. | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1554649A (zh) | 2004-12-15 |
AU2004202776B2 (en) | 2008-06-19 |
AU1531799A (en) | 1999-06-15 |
AU2004202776A1 (en) | 2004-07-22 |
NZ505207A (en) | 2003-10-31 |
IL136250A (en) | 2006-12-10 |
AU2004202776A2 (en) | 2004-07-22 |
MXPA00004940A (es) | 2002-10-17 |
CA2311131A1 (fr) | 1999-06-03 |
CN1285820A (zh) | 2001-02-28 |
WO1999026927A2 (fr) | 1999-06-03 |
EP1037878A2 (fr) | 2000-09-27 |
AU771358B2 (en) | 2004-03-18 |
JP2001524468A (ja) | 2001-12-04 |
IL136250A0 (en) | 2001-05-20 |
CN1158264C (zh) | 2004-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999026927A3 (fr) | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central | |
EP1595871A3 (fr) | Antagonistes du recepteur metabotrope duglutamate et leur utilisation pour le traitement des maladies du systeme nerveux central. | |
EP1679313A3 (fr) | Composés hétéropolycycliques et leur utilisation comme antagonistes du récepteur glutamate métabotropique | |
MY131442A (en) | Excitatory amino acid receptor antagonists | |
IL127244A (en) | Substituted amines, methods of their preparation and pharmaceutical compositions containing them | |
EP0686629A3 (fr) | Antagonistes des récepteurs de tachycinine cyclohexyliques | |
MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
WO1996019458A3 (fr) | Composes modulateurs des recepteurs des steroides et procedes d'utilisation | |
BG106762A (en) | Polycycloalkylpurines as adenosine receptor antagonists | |
AU3508497A (en) | Androgen receptor modulator compounds and methods | |
WO2001010846A3 (fr) | Nouveaux composes de 1,4-benzodiazepine et derives de ces derniers | |
HUP0002031A3 (en) | Use of benzotiophen derivatives for production pharmaceutical compositions having activity against central nervous system disorders | |
NO944578L (no) | Eksitatoriske aminosyre reseptor antagonister | |
FI945807A0 (fi) | 2,5-diokso-2,5-dihydro-1H-bents/b/atsepiinit NMDA-reseptorin antagonisteina | |
WO1996023769A3 (fr) | Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht¿2c? | |
WO1999029308A3 (fr) | Procede pour lutter contre l'obesite | |
GR3034354T3 (en) | IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
WO2004048318A8 (fr) | Procede ameliore pour la preparation d'indenes 1,3-substitutees | |
PL335501A1 (en) | Quinoxalinodiones | |
HK1031226A (en) | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 136250 Country of ref document: IL Ref document number: 98813148.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2311131 Country of ref document: CA Ref document number: 2311131 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/004940 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 522085 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15317/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 505207 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998959535 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998959535 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 15317/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 178023 Country of ref document: IL |